Literature DB >> 15281007

Type 2 diabetes and the genetics of signal transduction: a study of interaction between adenosine deaminase and acid phosphatase locus 1 polymorphisms.

N Bottini1, F Gloria-Bottini, P Borgiani, E Antonacci, P Lucarelli, E Bottini.   

Abstract

Acid phosphatase locus 1 (ACP1) is a highly polymorphic enzyme that has an important role in flavoenzyme activity and in the control of insulin receptor activity and band 3 protein phosphorylation status. Adenosine deaminase (ADA) is a polymorphic enzyme that catalyses the irreversible deamination of adenosine to inosine and has an important role in regulating adenosine concentration. Based on the hypothesis that ACP1 counteracts insulin signaling by dephosphorylating the insulin receptor and that adenosine has an anti-insulin action, we reasoned that low ACP1 activity (low dephosphorylating action on insulin receptor) when associated with high ADA activity (low adenosine concentration) would result in a cumulative effect towards an increased glucose tolerance. On the contrary, high ACP1 activity when associated with low ADA activity would result in a cumulative effect towards a decreased glucose tolerance. A total of 280 adult subjects with type 2 diabetes from the population of Penne (Italy) were studied. There was a nonsignificant trend toward an increase in the proportion of subjects with the complex type with high ACP1 activity and low ADA activity (ie, *B/*B; *A/*C; *B/*C; *C/*C//ADA*1/*2 and *2/*2) in type 2 diabetes relative to that observed in newborn infants from the same population. High ACP1 activity/low ADA activity joint genotype was positively associated with high glycemic levels and with high body mass index (BMI) values. Low ACP1 activity/high ADA activity joint genotype was also positively associated with dyslipidemia. These findings suggest that both ACP1 and ADA contribute to the clinical manifestations of type 2 diabetes and probably also have a marginal influence on susceptibility to the disease. Both additive and epistatic interactions between the 2 systems seem to be operative. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281007     DOI: 10.1016/j.metabol.2004.03.006

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Association analysis of SNPs in the IL4R locus with type I diabetes.

Authors:  H A Erlich; K Lohman; S J Mack; A M Valdes; C Julier; D Mirel; J A Noble; G E Morahan; S S Rich
Journal:  Genes Immun       Date:  2009-12       Impact factor: 2.676

2.  Evidence for association of the TCF7 locus with type I diabetes.

Authors:  H A Erlich; A M Valdes; C Julier; D Mirel; J A Noble
Journal:  Genes Immun       Date:  2009-12       Impact factor: 2.676

3.  Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.

Authors:  Stephanie M Stanford; Michael A Diaz; Robert J Ardecky; Jiwen Zou; Tarmo Roosild; Zachary J Holmes; Tiffany P Nguyen; Michael P Hedrick; Socorro Rodiles; April Guan; Stefan Grotegut; Eugenio Santelli; Thomas D Y Chung; Michael R Jackson; Nunzio Bottini; Anthony B Pinkerton
Journal:  J Med Chem       Date:  2021-04-29       Impact factor: 7.446

4.  The adenosine deaminase gene polymorphism is associated with chronic heart failure risk in Chinese.

Authors:  Hai-Rong He; Yuan-Jie Li; Gong-Hao He; Ya-Jun Wang; Ya-Jing Zhai; Jiao Xie; Wei-Peng Zhang; Ya-Lin Dong; Jun Lu
Journal:  Int J Mol Sci       Date:  2014-08-28       Impact factor: 5.923

5.  A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats.

Authors:  Yaiza Forcada; Mike Boursnell; Brian Catchpole; David B Church
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.